Literature DB >> 3104694

Repeat sternotomy after reconstruction of the pericardial sac with glutaraldehyde-preserved equine pericardium.

L von Segesser, N Jornod, B Faidutti.   

Abstract

The risk of repeat sternotomy is higher than that of the initial sternotomy, especially if the pericardial sac was left open at the first intervention. In 200 consecutive patients with a pericardial defect after open heart operations, the pericardium was closed with a glutaraldehyde-preserved equine pericardial patch. Precardiac adhesions at reoperation were assessed in four groups of patients on a scale of 6, ranging from 0 (no adhesions) to 5 (calcified or ossified adhesions). Group I comprised 13 patients in whom the pericardium was left open at the first operation and an equine pericardial patch was implanted at reoperation. Group Ia included the first five Group I patients who underwent reoperation less than 1 year (early reoperation) after the initial procedure. Group Ib included the other eight patients of Group I, who underwent reoperation more than 1 year (late reoperation) after the first procedure. Group II comprised nine patients who were reoperated on after reconstruction of the pericardial sac with a glutaraldehyde-preserved equine pericardial patch. After a mean follow-up of 20.2 months, the incidence of patch-related complications was 1%. Statistical analysis shows less severe adhesions on reoperation in Group II patients (pericardial defect patched) than in Group I patients (pericardial defect left open): mean grade of adhesions 1.6 +/- 0.9 (Group II) versus 3.2 +/- 0.6 (Group I), p less than 0.001. Precardial adhesions with the pericardium left open were similar in patients having early and late reoperations: mean grade of adhesions 3.0 +/- 0.7 (Group Ia) versus 3.4 +/- 0.5 (Group Ib), no significant difference. Therefore, the glutaraldehyde-preserved equine pericardial patch can be considered a suitable material for primary closure of the pericardial sac in patients with inadequate autologous pericardium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104694

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  In vitro study in the endothelial cell compatibility and endothelialization of genipin-crosslinked biological tissues for tissue-engineered vascular scaffolds.

Authors:  Yu Xi-xun; Liu Fei; Xu Yuan-ting; Wan Chang-xiu
Journal:  J Mater Sci Mater Med       Date:  2010-02       Impact factor: 3.896

Review 2.  Bioengineered tissue solutions for repair, correction and reconstruction in cardiovascular surgery.

Authors:  Laura Iop; Tiziana Palmosi; Eleonora Dal Sasso; Gino Gerosa
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Endovascular treatment of internal carotid and vertebral artery aneurysms using a novel pericardium covered stent.

Authors:  I Vulev; A Klepanec; R Bazik; T Balazs; R Illes; J Steno
Journal:  Interv Neuroradiol       Date:  2012-06-04       Impact factor: 1.610

4.  Repair of gastric defects with an equine pericardial patch.

Authors:  Kostantinos Spiliopoulos; Charalampos Markakis; Periklis Tomos; Hariklia Gakiopoulou; Ioannis Nikolopoulos; Eleftherios Spartalis; Kostantinos Kontzoglou; Michael Safioleas
Journal:  Surg Today       Date:  2014-11-08       Impact factor: 2.549

5.  Use of polytetrafluoroethylene surgical membrane as a pericardial substitute in the correction of congenital heart defects.

Authors:  M Loebe; V Alexi-Meskhishvili; Y Weng; G Hausdorf; R Hetzer
Journal:  Tex Heart Inst J       Date:  1993

6.  Equine pericardium: a versatile alternative reconstructive material in congenital cardiac surgery.

Authors:  Ahmed Abdelrahman Elassal; Osman Osama Al-Radi; Zaher Faisal Zaher; Ahmed Mohamed Dohain; Gaser Abdelmohsen Abdelmohsen; Ragab Sayed Mohamed; Mazin Adel Fatani; Mohamed Esam Abdelmotaleb; Nada Ahmed Noaman; Mahmoud Akl Elmeligy; Osama Saber Eldib
Journal:  J Cardiothorac Surg       Date:  2021-04-23       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.